KV Pharmaceutical (KV.a) Announces Acquisition of Rights to Gestiva
More News related to KV.A
- Unusual 11 Mid-Day Movers 9/2: KV.A, PAY, MDCO, MDZ Higher; DHT, SEAC, SVA, SYNO Lower
- KV Pharmaceutical (KV.A) Announces Licensing Agreement with Gedeon Richter
- Unusual 11 Mid-Day Movers 1/26: BCS, ZQK, IRE, LYG Higher; KV.A, PVTB, ROH, WBS Lower
- Unusual 11 Mid-Day Movers 12/24: LCAPA, PLD, RMBS, VLY Higher; KV, YRCW, EPIX, VIP Lower
- Notable Analyst Rating Changes 12/24: PLD, SLF, SUPX Upgraded; AMAG, CCJ, KV Downgraded
More News related to KV.B
- KV Pharmaceutical (KV.A) Announces Licensing Agreement with Gedeon Richter
- KV Pharmaceutical (KV.a) Announces Acquisition of Rights to Gestiva
KV Pharmaceutical Company (NYSE: KV.a) (NYSE: KV.b) entered into a definitive purchase agreement that gives KV full U.S. and worldwide rights to Gestiva upon approval of the pending Gestiva New Drug Application.
The NDA for Gestiva is currently before the FDA, pending approval for use in the prevention of preterm birth in certain categories of pregnant women.
Related Categories
FDAMergers and Acquisitions
Stocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
